Open Access

Erratum to: Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer

BMC Cancer201414:892

Received: 18 November 2014

Accepted: 27 November 2014

Published: 3 December 2014

The original article was published in BMC Cancer 2013 13:539


After publication of this article ([1]) we noted errors in the references. The term ‘Fau’ with varying initials has been included amongst the names of the authors in about a half of the citations, while the fist author of these articles has been omitted. A corrected reference list can be found below:

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Canc J Clin 2011, 61:69–90.

2. Kollarova H, Machova L, Horakova D, Janoutova G, Janout V: Epidemiology of esophageal cancer–an overview article. Biomed Papers Med Faculty University Palacky Olomouc Czechoslovakia 2007, 151:17–20.

3. Simard EP, Ward EM, Siegel R, Jemal A: Cancers with increasing incidence trends in the United States: 1999 through 2008. LID - 10.3322/caac.20141 [doi]. CA Canc J Clin 2012, 4:20141.

4. Vial M, Grande L, Pera M: Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Canc Res 2010, 182:1–17.

5. Gavin AT, Francisci S, Foschi R, Donnelly DW, Lemmens V, Brenner H, Anderson LA: Oesophageal cancer survival in Europe: A EUROCARE-4 study. Canc Epidemiol 2012, 36:505–512.

6. Cen P, Banki F, Cheng L, Khalil K, Du XL, Fallon M, Amato RJ, Kaiser LR: Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States. Ann Surg Oncol 2012, 19:1685–1691.

7. Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Gordon HS, Stewart AK, Ko CY, Bentrem DJ: Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Cancer 2012, 118:3268–3276.

8. Blom RL, Lagarde SM, Klinkenbijl JHG, Busch OR,van Berge Henegouwen MI: A high body mass index in esophageal cancer patients does not influence postoperative outcome or long-term survival. Ann Surg Oncol 2012, 19:766–771. Epub 2011 Oct 2017.

9. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93:387–391.

10. Altman DG: Systematic reviews of evaluations of prognostic variables. BMJ 2001, 323:224–228.

11. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001, 18:705–719.

12. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646–674.

13. DerSimonian R, Laird N: Meta-analysis in clinical trials. Contr Clin Trials 1986, 7:177–188.

14. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557–560.

15. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088–1101.

16. Song F, Gilbody S: Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ 1998, 316:471.

17. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629–634.

18. Nabeya Y, Shimada H, Okazumi S, Matsubara H, Gunji Y, Suzuki T, Ochiai T: Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma. Cancer 2002, 94:940–949.

19. Yoon HH, Shi Q , Sukov WR, Wiktor AE, Khan M, Sattler CA , Grothey A, Wu T-T, Diasio RB, Jenkins RB, Sinicrope FA: Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012, 18:546–554.

20. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimaki A: Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002, 122:1800–1807.

21. Nozoe T, Ezaki T, Kabashima A, Baba H, Maehara Y: Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg 2005, 189:110–115.

22. Sivula A, Buskens CJ, van Rees BP, Haglund C, Offerhaus GJ, van Lanschot JJ, Ristimaki A: Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int J Canc J Int Canc 2005, 116:903–908.

23. Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di Nicolantonio F, Patel P: Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Canc 2006, 6:134.

24. Yoon MS, Nam T-K, Lee J-S, Cho S-H, Song J-Y, Ahn S-J, Chung I-J, Jeong J-U, Chung W-K, Nah B-S: VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. J Korean Med Sci 2011, 26:513–520. Epub 2011 Mar 2028.

25. Huang JX, Chen WC, Lin M, Zhang YL, Li FY, Song ZX, Xiao W, Chen P, Qian RY, Salminen E, Yu H: Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma. Dis Esophagus Off J Int Soc Dis Esophagus / ISDE 2012, 25:121–129.

26. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M: In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998, 77:1704–1709.

27. Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, Kano M: Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999, 80:1281–1288.

28. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Canc Res Offic J Am Assoc Canc Res 2000, 6:1161–1168.

29. Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T: Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001, 92:663–669.

30. Ahn MJ, Jang SJ, Park YW, Choi JH, Oh HS, Lee CB, Paik HK, Park CK: Clinical prognostic values of vascular endothelial growth factor, microvessel density, and p53 expression in esophageal carcinomas. J Kor Med Sci 2002, 17:201–207.

31. Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Tsukada K, Kuwano H: Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 2002, 22:3977–3984.

32. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, Hayashi H, Takeda A, Shiratori T, Uno T, et al.: Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Canc 2002, 86:552–557.

33. Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K: Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J Surg 2003, 27:584–589. Epub 2003 Apr 2028.

34. Rosa AR, Schirmer CC, Gurski RR, Meurer L, Edelweiss MI, Kruel CD: Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis Esophagus Offic J Int Soc Dis Esophagus / ISDE 2003, 16:112–118.

35. Dreilich M, Wagenius G, Bergstrom S, Brattstrom D, Larsson A, Hesselius P, Bergqvist M: The role of cystatin C and the angiogenic cytokines VEGF and bFGF in patients with esophageal carcinoma. Med Oncol 2005, 22:29–38.

36. Choi JY, Jang KT, Shim YM, Kim K, Ahn G, Lee KH, Choi Y, Choe YS, Kim BT: Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography. Ann Surg Oncol 2006, 13:1054–1062.

37. Kii T, Takiuchi H, Kawabe S, Gotoh M, Ohta S, Tanaka T, Kuwakado S, Nishitani H, Katsu K: Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens. Jpn J Clin Oncol 2007, 37:583–589.

38. Inoue A, Moriya H, Katada N, Tanabe S, Kobayashi N, Watanabe M, Okayasu I, Ohbu M: Intratumoral lymphangiogenesis of esophageal squamous cell carcinoma and relationship with regulatory factors and prognosis. Pathol Int 2008, 58:611–619.

39. Tzao C, Lee S-C, Tung H-J, Hsu H-S , Hsu W-H, Sun G-H, Yu C-P, Jin J-S, Cheng YL: Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers 2008, 25:141–148.

40. Cavazzola L, Rosa ARP, Schirmer CC, Gurski RR, Telles JPB, Mielke F, Meurer L, Edelweiss MIA, Kruel CD: Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma. Rev Col Bras Cir 2009, 36:24–34.

41. Liu P, Chen W, Zhu H, Liu B, Song S, Shen W, Wang F, Tucker S, Zhong B, Wang D: Expression of VEGF-C correlates with a poor prognosis based on analysis of prognostic factors in 73 patients with esophageal squamous cell carcinomas. Jpn J Clin Oncol 2009, 39:644–650.

42. Kozlowski M, Kowalczuk O, Milewski R, Chyczewski L, Niklinski J, Laudanski J: Serum vascular endothelial growth factors C and D in patients with oesophageal cancer. Eur J Cardio-thoracic Surg Offic J Eur Assoc Cardio-thoracic Surg 2010, 38:260–267.

43. Tanaka T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, Shiozaki M, Naganawa Y, Fujii Y, Takeyama H: Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Canc Res: CR 2010, 29:83.

44. Sun ZG, Wang Z, Liu XY, Liu FY: Mucin 1 and vascular endothelial growth factor C expression correlates with lymph node metastatic recurrence in patients with N0 esophageal cancer after Ivor-Lewis esophagectomy. World J Surg 2011, 35:70–77.

45. Mega S, Miyamoto M, Li L, Kadoya M, Takahashi R, Hase R, Kaneko H, Shichinohe T, Kawarada Y, Itoh T, Morikawa T, et al.: Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma. Dis Esophagus: Offic J Int Soc Dis Esophagus / ISDE 2006, 19:355–359.

46. Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, Mandruzzato S, Del Bianco P, Ruol A, Zaninotto G, Zanovello P: Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 2006, 119:1717–1722.

47. Hsu KF, Lin CK, Yu CP, Tzao C, Lee SC, Lee YY, Tsai WC, Jin JS: Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus: Offic J Int Soc Dis Esophagus / ISDE 2009, 22:402–408.

48. Hoffmann AC, Vallbohmer D, Grimminger P, Metzger R, Prenzel KL, Hoelscher AH, Brabender J: Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics 2010, 11:341–347.

49. Takeno S, Yamashita S, Takahashi Y, Ono K, Kamei M, Moroga T, Kawahara K: Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression. Eur J Cardio-thoracic Surg: Offic J Eur Assoc Cardio-thoracic Surg 2010, 37:440–445.

50. Sarbia M, Stahl M, zur Hausen A, Zimmermann K, Wang L, Fink U, Heep H, Dutkowski P, Willers R, Muller W, et al.: Expression of p21WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin Canc Res Offic J Am Assoc Canc Res 1998, 4:2615–2623.

51. Hirai T, Kuwahara M, Yoshida K, Osaki A, Toge T: The prognostic significance of p53, p21 (Waf1/Cip1), and cyclin D1 protein expression in esophageal cancer patients. Anticancer Res 1999, 19:4587–4591.

52. Natsugoe S, Nakashima S, Matsumoto M, Xiangming C, Okumura H, Kijima F, Ishigami S, Takebayashi Y, Baba M, Takao S, Aikou T: Expression of p21WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res 1999, 5:2445–2449.

53. Nita ME, Nagawa H, Tominaga O, Tsuno N, Hatano K, Kitayama J, Tsuruo T, Domene CE, Muto T: p21Waf1/Cip1 expression is a prognostic marker in curatively resected esophageal squamous cell carcinoma, but not p27Kip1, p53, or Rb. Ann Surg Oncol 1999, 6:481–488.

54. Matsumoto M, Furihata M, Kurabayashi A, Sasaguri S, Araki K, Hayashi H, Ohtsuki Y: Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma. Oncology 2004, 67:143–150.

55. Nakamura T, Hayashi K, Ota M, Ide H, Takasaki K, Mitsuhashi M: Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis Esophagus 2004, 17:315–321.

56. Goan Y-G, Hsu H-K, Chang H-C, Chou Y-P, Chiang K-H, Cheng JT: Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients. Ann Thorac Surg 2005, 80:1007–1016.

57. Taghavi N, Biramijamal F, Sotoudeh M, Moaven O, Khademi H, Abbaszadegan MR, Malekzadeh R: Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol: WJG 2010, 16:4958–4967.

58. Anayama T, Furihata M, Ishikawa T, Ohtsuki Y, Ogoshi S: Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. Int J Cancer 1998, 79:439–443.

59. Itami A, Shimada Y, Watanabe G, Imamura M: Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 1999, 57:311–317.

60. Yasunaya M, Tabira Y, Kondo K, Okuma T, Kitamura N: The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy. Dis Esophagus: Offic J Int Soc Dis Esophagus / ISDE 1999, 12:120–127.

61. Shamma A, Doki Y, Tsujinaka T, Shiozaki H, Inoue M, Yano M, Kawanishi K, Monden M: Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology 2000, 58:152–158.

62. Shiozaki H, Doki Y, Kawanishi K, Shamma A, Yano M, Inoue M, Monden M: Clinical application of malignancy potential grading as a prognostic factor of human esophageal cancers. Surgery 2000, 127:552–561.

63. Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T, Fujiwara Y, Yano M, Miyata H, Kishi K, et al.: Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br J Canc 2001, 85:412–421.

64. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seeber S, Gabbert HE: Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Canc 1999, 84:86–91.

65. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases: Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. J Am Coll Surg 2001, 192:708–718.

66. Ikeguchi M, Sakatani T, Ueta T, Kaibara N: Cyclin D1 expression and retinoblastoma gene protein (pRB) expression in esophageal squamous cell carcinoma. J Canc Res Clin Oncol 2001, 127:531–536.

67. Nagasawa S, Onda M, Sasajima K, Makino H, Yamashita K, Takubo K, Miyashita M: Cyclin D1 overexpression as a prognostic factor in patients with esophageal carcinoma. J Surg Oncol 2001, 78:208–214.

68. Shinohara M, Aoki T, Sato S, Takagi Y, Osaka Y, Koyanagi Y, Hatooka S, Shinoda M: Cell cycle-regulated factors in esophageal cancer. Dis Esophagus Offic J Int Soc Dis Esophagus / ISDE 2002, 15:149–154.

69. Guner D, Sturm I, Hemmati P, Hermann S, Hauptmann S, Wurm R, Budach V, Dorken B, Lorenz M, Daniel PT: Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 2003, 103:445–454.

70. Fukuchi M, Fukai Y, Kimura H, Sohda M, Miyazaki T, Nakajima M, Masuda N, Tsukada K, Kato H, Kuwano H: Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int J Oncol 2006, 29:329–334.

71. Takeshita H, Ichikawa D, Komatsu S, Tsujiura M, Kosuga T, Deguchi K, Konishi H, Morimura R, Shiozaki A, Fujiwara H, Okamoto K, et al.: Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma. Br J Canc 2010, 102:1378–1383. Epub 2010 Apr 1313.

72. Wang MT, Chen G, An SJ, Chen ZH, Huang ZM, Xiao P, Ben XS, Xie Z, Chen SL, Luo DL, Tang JM, et al.: Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma. Dis Esophagus 2012, 25:664–670. doi:610.1111/j.1442-2050.2011.01291.x. Epub 02011 Dec 01299.

73. Chanvitan A, Nekarda H, Casson AG: Prognostic value of DNA index, S-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous-cell carcinomas in Thailand. Int J Canc J Int Canc 1995, 63:381–386.

74. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H: p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol 1998, 51:71–79.

75. Pomp J, Davelaar J, Blom J, van Krimpen C, Zwinderman A, Quint W, Immerzeel J: Radiotherapy for oesophagus carcinoma: the impact of p53 on treatment outcome. Radiother Oncol J Eur Soc Ther Radiol Oncol 1998, 46:179–184.

76. Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H, Yamaguchi H, Gotoda T, Muro K, Matsumura Y: No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol 1999, 72:94–98.

77. Kuwahara M, Hirai T, Yoshida K, Yamashita Y, Hihara J, Inoue H, Toge T: p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus Offic J Int Soc Dis Esophagus / ISDE 1999, 12:116–119.

78. Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N: Combined analysis of p53 and retinoblastoma protein expressions in esophageal cancer. Ann Thorac Surg 2000, 70:913–917.

79. Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, Becker K, Dittler HJ, Fink U, Siewert JR: P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Canc Res Offic J Am Assoc Canc Res 2000, 6:3153–3158.

80. Aloia TA, Harpole DH Jr, Reed CE, Allegra C, Moore MB, Herndon JE 2nd, D'Amico TA: Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001, 72:859–866.

81. Berggvist AS, Bergqvist M, Brattstrom D, Hesselius P, Larsson A, Brodin O, Wagenius G: Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res 2001, 21:4141–4145.

82. Makoto O, Takeda A, Ting-Leig L, Shinnichi O, Hisahiro M, Yutaka F, Yoshihiro N, Kobayashi S, Gunji Y, Suzuki T, Takenori O, et al.: Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol Rep 2002, 9:23–28.

83. Noguchi T, Takeno S, Shibata T, Uchida Y, Yokoyama S, Muller W: Expression of heat shock protein 70 in grossly resected esophageal squamous cell carcinoma. Ann Thorac Surg 2002, 74:222–226.

84. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, Hayashi H, Takeda A, Ochiai T: Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002, 132:41–47.

85. Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Muller W: Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer 2002, 94:2874–2881.

86. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A: Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Canc Res Offic J Am Assoc Canc Res 2003, 9:6461–6468.

87. Ikeguchi M, Yamaguchi K, Kaibara N: Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med 2003, 24:40–45.

88. Kunisaki C, Imada T, Yamada R, Hatori S, Kinbara K, Watai K, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono H, et al.: Prognostic factors after chemoradiotherapy for patients with inoperable esophageal squamous cell carcinoma. Hepatogastroenterology 2006, 53:366–371.

89. Hsu PK, Li AF-Y, Wang Y-C, Hsieh C-C, Huang M-H, Hsu W-H, Hsu HS: Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. J Thorac Cardiovasc Surg 2008, 135:1029–1035.

90. Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, Matsubara H, Nomura F, Ochiai T: Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 2008, 33:272–277.

91. Cheng T-H, Hsu P-K, Li AF-Y, Hung IC, Huang M-H, Hsu HS: Correlation of p53, MDM2 and p14(ARF) protein expression in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2009, 135:1577–1582. Epub 2009 Jun 1572.

92. Okumura H, Kita Y, Yokomakura N, Uchikado Y, Setoyama T, Sakurai H, Omoto I, Matsumoto M, Owaki T, Ishigami S, Natsugoe S: Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res 2010, 30:5175–5179.

93. Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T, Yasuda T, Matsuyama J, Mori M, Doki Y: p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol 2010, 17:634–642. Epub 2009 Nov 2026.

94. Yen C-C, Tsao Y-P, Chen PC-H, Wu Y-C, Liu J-H, Pan C-C, Liu C-Y, Tzeng C-H, Chen P-M, Chen Y-J, Lin C-H, et al.: PML protein as a prognostic molecular marker for patients with esophageal squamous cell carcinomas receiving primary surgery. J Surg Oncol 2011, 103:761–767. 710.1002/jso.21855. Epub 22011 Jan 21815.

95. Blanchard P, Quero L, Pacault V, Schlageter MH, Baruch-Hennequin V, Hennequin C: Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy. BMC Canc 2012, 12:119.

96. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, Becker K, Siewert JR, Harbec N: Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994, 73:1785–1794.

97. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H: Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005, 92:1253–1260.

98. Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G, Bergqvist M: HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006, 19:224–231.

99. Rauser S, Weis R, Braselmann H, Feith M, Stein HJ, Langer R, Hutzler P, Hausmann M, Lassmann S, Siewert JR, Hofler H, et al.: Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 2007, 13:5115–5123.

100. Berg D, Wolff C, Langer R, Schuster T, Feith M, Slotta-Huspenina J, Malinowsky K, Becker KF: Discovery of new molecular subtypes in oesophageal adenocarcinoma. PloS One 2011, 6:e23985. doi: 10.1371/journal.pone.0023985. Epub 2011 Sep 23.

101. Kato H, Nakajima M, Masuda N, Faried A, Sohda M, Fukai Y, Miyazaki T, Fukuchi M, Tsukada K, Kuwano H: Expression of RCAS1 in esophageal squamous cell carcinoma is associated with a poor prognosis. J Surg Oncol 2005, 90:89–94.

102. Falkenback D, Nilbert M, Oberg S, Johansson J: Prognostic value of cell adhesion in esophageal adenocarcinomas. Dis Esophagus 2008, 21:97–102.

103. Zhao XJ, Li H, Chen H, Liu Y-X, Zhang L-H, Liu S-X, Feng QL: Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol 2003, 9:225–232.

104. Shimada Y, Hashimoto Y, Kan T, Kawamura J, Okumura T, Soma T, Kondo K, Teratani N, Watanabe G, Ino Y, Sakamoto M, et al.: Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology 2004. City.

105. Takeno S, Noguchi T, Fumoto S, Kimura Y, Shibata T, Kawahara K: E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. Am J Clin Pathol 2004, 122:78–84.

106. Natsugoe S, Uchikado Y, Okumura H, Matsumoto M, Setoyama T, Tamotsu K, Kita Y, Sakamoto A, Owaki T, Ishigami S, Aikou T: Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep 2007, 17:517–523.

107. Setoyama T, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Yokomakura N, Ishigami S, Aikou T: alpha-catenin is a significant prognostic factor than E-cadherin in esophageal squamous cell carcinoma. J Surg Oncol 2007, 95:148–155.

108. Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K, Sakamoto A, Owaki T, et al.: Significance of Twist expression and its association with E-cadherin in esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2009, 28:158.

109. Chung Y, Law S, Kwong DL, Luk JM: Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus 2011, 24:49–55. 10.1111/j.1442-2050.2010.01093.x. Epub 02010 Aug 01030.

110. Nozoe T, Saeki H, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001, 182:197–201.

111. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T: Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003, 238:197–202.

112. Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y, Sugimachi K: Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker. Cancer Lett 2003, 192:89–95.

113. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003, 83:248–252.

114. Gockel I, Dirksen K, Messow C-M, Junginger T: Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 2006, 12:3746–3750.

115. Wang C-Y, Hsieh M-J, Chiu Y-C, Li S-H, Huang H-W, Fang F-M, Huang YJ: Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 2009, 92:270–275. Epub 2009 Feb 2003.

116. Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG: Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg 2010, 14:462–469. Epub 2009 Nov 2025.

117. Nakatsu T, Motoyama S, Fa Maruyama K, Usami S, Sato Y, Miura M, Hinai Y, Saito H, Minamiya Y, Murata K, Ogawa J: Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg Today 2012, 42:652–658. Epub 2012 Feb 2021.

118. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T: Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003, 133:486–494.

119. Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K: Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19–9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg 2004, 28:680–685.

120. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E, Imamura M: Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 2005, 68:285–292.

121. Cao M, Yie SM, Wu SM, Chen S, Lou B, He X, Ye SR, Xie K, Rao L, Gao E, Ye NY: Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 2009, 26:751–758.

122. Brattstrom D, Wagenius G, FSandstrom P, Dreilich M, Bergstrom S, Goike H, Hesselius P, Bergqvist M: Newly developed assay measuring cytokeratins 8, 18 and 19 in serum is correlated to survival and tumor volume in patients with esophageal carcinoma. Dis Esophagus 2005, 18:298–303.

123. Valencia Julve J, Alonso Orduna V, Esco Baron R, Lopez-Mata M, Mendez Villamon A: Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Translational Oncol Offic Publ Federation Spanish Oncol Soc Nat Canc Inst Mexico 2006, 8:22–30.

124. Zhao KL, Liu G, Jiang GL, Wang Y, Zhong LJ, Yao WQ, Guo XM, Wu GD, Zhu LX, Shi XH: Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy--a secondary analysis of three consecutive clinical phase III trials. Clin Oncol (R Coll Radiol) 2006, 18:621–627.

125. Rades D, Golke H, Schild SE, Kilic E: Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy. Strahlenther Onkol Organ Deutschen Rontgengesellschaft [et al.] 2008, 184:416–420.

126. Zenda S, Hironaka S, Boku N, Yamazaki K, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Nishimura T: Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus Offic J Int Soc Dis Esophagus / ISDE 2008, 21:195–200.

127. Gould Rothberg BE, Bracken MB, Rimm DL: Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Canc Inst 2009, 101:452–474.

128. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M, Abrams KR, Moreno S, McAllister KS, Palmer S, Kaski JC, et al.: Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PloS Med 2010, 7:e1000286. doi: 10.1371/journal.pmed.1000286.

129. Mrena J, Wiksten J-P, Kokkola A, Nordling S, Ristimaki A, Haglund C: COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 2010, 31:1–7. 10.1007/s13277-13009-10001-13274. Epub 12009 Dec 13218.

130. Chen J, Li T, Wu Y, He L, Zhang L, Shi T, Yi Z, Liu M, Pang X: Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Canc Res Clin Oncol 2011, 137:1799–1812.

131. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Canc 2006, 94:1823–1832.

132. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Canc 2008, 8:61–70.

133. Lee MH, Yang HY: Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol life Sci: CMLS 2001, 58:1907–1922.

134. Chu IM, Hengst L, Slingerland JM: The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Canc 2008, 8:253–267.

135. Al-Maghrabi J, Al-Ahwal M, Buhmeida A, Syrjanen K, Sibyani A, Emam E, Ghanim A, Al-Qahtani M: Expression of cell cycle regulators p21 and p27 as predictors of disease outcome in colorectal carcinoma. J Gastrointest Canc 2012, 43:279–287.

136. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW: Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213:374–383.

137. Hirohashi S, Kanai Y: Cell adhesion system and human cancer morphogenesis. Canc Sci 2005, 94:575–581.

138. Gaarenstroom KN, Kenter GG, Bonfrer JMG, Korse CM, Van de Vijver MJ, Fleuren GJ, Trimbos JB: Can initial serum cyfra 21–1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol 2000, 77:164–170.

139. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM: Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002, 69:25–29.

140. Mahmoud FA, Rivera NI: The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002, 4:250–255.

141. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088–1101.


Authors’ Affiliations

Department of Preventive Medicine, Shantou University Medical College


  1. Meilan C, Jizheng H, Zhenli Z, Jun Z, Ke L: Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer. 2013, 13: 539-10.1186/1471-2407-13-539.View ArticleGoogle Scholar
  2. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:


© Chen et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.